GMP: New WHO guidance on variations to multisource pharmaceutical products

The World Health Organizaton recently published a new Annex 10: WHO general guidance on variations to multisource pharmaceutical products. The document is \"intended to serve as a guide for ...

RAPS: DA Begins Process of Overhauling Off-Label Communications Regulations

The US Food and Drug Administration (FDA) on Wednesday announced a new two-day public meeting to address a comprehensive review of its regulations and policies governing firms’ off-label ...

RAPS: FDA Calls for Boxed Warning on Two Drug Classes

The US Food and Drug Administration (FDA) says it is requiring two classes of drugs, opioids and benzodiazepines, to bear a boxed warning over serious and sometimes fatal risks when the two drugs ...

RAPS: FDA Makes Drug Safety Labeling Change Information Easier to Access

The US Food and Drug Administration (FDA) on Thursday announced the safety labeling changes (SLC) program will be managed by its Center for Drug Evaluation and Research’s (CDER’s) Office of ...

GMP: EMA - requirements for quality documentation concerning biological investigational medicinal products

Already in 2012, the European Commission published a guideline on the quality documentation for IMP in clinical trials. Now on 23 June, the EMA issued a draft \"Guideline on the requirements for ...

FDA: E17 General Principles for Planning and Design of Multi-Regional Clinical Trials This

With the increasing globalisation of drug development, it has become important that data from multi-regional clinical trials (MRCTs) can be accepted by regulatory authorities across regions and ...

FDA: Microbiology Data for Systemic Antibacterial Drugs — Development, Analysis, and Presentation

The purpose of this guidance is to assist sponsors in the development, analysis, and presentation of microbiology data during antibacterial drug development. Specifically, this guidance addresses ...

EMA: EU collaboration strengthens safety monitoring of medicines

European Commission publishes three-year report on implementation of pharmacovigilance legislation. Closer collaboration between the European Medicines Agency (EMA), the European Commission and ...

EMA: Draft vandetanib film-coated tablets 100 and 300 mg product-specific bioequivalence guidance

This document provides product-specific guidance on the demonstration of the bioequivalence of vandetanib. ...

EMA: Draft guideline on good pharmacovigilance practices (GVP) - Module VI – Management and reporting of adverse reactions to medicinal products (Rev. 2)

This Module of GVP addresses the legal requirements detailed in Title IX of Directive 2001/83/EC 183 and Chapter 3 of Title II of Regulation (EC) No 726/2004, which are applicable to competent ...

kapitał ludzki

fundusz społeczny

Narodowe Centrum Badań i Rozwoju

innowacyjna gospodarka

rozwój regionalny